Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute (NCI) is inviting grant applications for exploratory research projects aimed at advancing and validating new technologies that enhance the handling, analysis, targeting, probing, or quality control of biospecimens in cancer research. This opportunity, part of the Innovative Molecular Analysis Technologies (IMAT) Program, targets R33 applications where preliminary data already demonstrate key feasibility milestones but further development and validation are necessary to facilitate broader adoption by the research community. Proposals must focus on cancer applications and demonstrate potential to accelerate progress in cancer biology, early detection, clinical diagnosis, treatment, control, epidemiology, or address cancer health disparities. The solicitation explicitly excludes projects where the innovation is solely in the biological or clinical question rather than the technology itself. This funding opportunity is not designed for clinical trials and encourages technologies that could have broad applicability across basic and clinical cancer research but must remain centered on cancer-related applications. The initiative supports technologies that overcome major technical barriers, aiming to foster novel capabilities that can significantly improve cancer research practices. Interested applicants can contact Dr. Kelly Crotty for further information, and the application was posted by the Department of Health and Human Services through the National Institutes of Health on September 8, 2025.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, analyzing, handling, or performing quality control of biospecimens used for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
